Corleen M. Roche - 06 Aug 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Reporting relationship: Chief Financial Officer
Issuer ticker: IOVA
Reported as of: 06 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2025, 16:06:19 UTC
Prior SEC filing: 16 Apr 2025
Next SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Corleen Roche

Key filing fact

Corleen M. Roche filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 08 Aug 2025.

Key facts

This page summarizes Corleen M. Roche's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 Aug 2025, 16:06.

Change

Previous filing in this sequence was filed on 16 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857905 Primary reporting owner

Roche Corleen M.

Relationship: Chief Financial Officer
Address: C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS
Signature: /s/ Corleen Roche
Signature date: 08 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOVA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 06 Aug 2025
Ownership: Direct
Underlying class: Common stock
Underlying amount: 300,000
Exercise price: $2.58
Footnotes: F1

IOVA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 06 Aug 2025
Ownership: Direct
Underlying class: Common stock
Underlying amount: 150,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's common stock.